G protein-coupled receptors (GPCRs) are a superfamily of proteins that include some of the most important drug targets in the pharmaceutical industry. Despite the success of this group of drugs, there remains a need to identify GPCR-targeted drugs with greater selectivity, to develop screening assays for validated targets, and to identify ligands for orphan receptors. To address these challenges, the authors have created a multiplexed GPCR assay that measures greater than 3000 receptor:ligand interactions in a single microplate. The multiplexed assay is generated by combining reverse transfection in a 96-well plate format with a calcium flux readout. This assay quantitatively measures receptor activation and inhibition and permits the determination of compound potency and selectivity for entire families of GPCRs in parallel. To expand the number of GPCR targets that may be screened in this system, receptors are cotransfected with plasmids encoding a promiscuous G protein, permitting the analysis of receptors that do not normally mobilize intracellular calcium upon activation. The authors demonstrate the utility of reverse transfection cell microarrays to GPCR-targeted drug discovery with examples of ligand selectivity screening against a panel of GPCRs as well as dose-dependent titrations of selected agonists and antagonists. (Journal of Biomolecular
INTRODUCTION
A N ESTIMATED 747 GENES IN THE HUMAN GENOME are dedicated to a single gene family-the G protein-coupled receptors (GPCRs). 1 This number reflects the biological importance of GPCRs and their involvement in a wide variety of cellular processes. GPCR-mediated signal transduction provides a primary means by which cells survey the extracellular environment, transmit external biochemical signals to intracellular relay systems, and translate those signals into a specific physiological response. The pivotal role of GPCR-mediated signaling in cellular metabolism has positioned these receptors as prime therapeutic targets, as illustrated by the fact that 40% of all currently marketed drugs are directed against approximately 30 GPCRs. 2 This group, however, represents a relatively modest proportion of the total estimated number of potentially druggable GPCR targets. In addition, there is a substantial pool of functionally uncharacterized GPCRs repre-senting an untapped resource in drug discovery. Of the 747 predicted human GPCRs, 380 are chemosensory receptors for environmental stimuli such as odorants or taste, whereas the remaining 367 are predicted to bind endogenous ligands. 1 Within this group of 367 GPCRs, ligands have been identified for only 224, leaving more than 140 orphan GPCRs for which neither ligands nor functions have yet been defined. 1 Tapping into the therapeutic potential of the 367 nonchemosensory GPCRs requires identifying ligands and functions for the orphan receptors, rapidly developing screening assays for all receptors, and identifying agonists or antagonists with a desired selectivity profile.
A major technical advance in GPCR biology and drug screening was made possible by the observation that the Gα 16 class of G protein α subunits is capable of coupling to a wide range of GPCRs in contrast to the more stringent specificities exhibited by the majority of other known Gα subunits. 3 G protein α subunits are traditionally sorted into 4 major groups (G s , G i , G q , and G 12/13 ) based on their sequence similarity. 4 This taxonomy provides a general parameter for defining the specificity of α subunit interactions with GPCRs and downstream effectors. As a member of the G q family, Gα 16 acts through phospholipase C-β to trigger the release of intracellular pools of calcium. Ligand-induced activation of a GPCR that is channeled through Gα 16 can then be detected using a calcium-sensitive fluorophore dye such as Fluo-4™ (Molecular Probes, Eugene, OR) in conjunction with an automated fluores-cence imaging system such as FLIPR-(Molecular Devices, Sunnyvale, CA).
Creating a functional screen for GPCRs that is independent of the G protein associated with the receptor has significant applications in GPCR "de-orphaning" and screening. By coupling receptor activation to an easily detected change in cell physiology using promiscuous Gα 16 , or one of several other engineered promiscuous chimeric G proteins, [5] [6] [7] [8] ligands for some orphan GPCRs have been elucidated. 9, 10 For de-orphaning, the cotransfection of GPCR and promiscuous G protein into an appropriate cell line permits a GPCR to be challenged with a wide array of ligands and tested for ligand-induced stimulation of intracellular calcium flux. Although no promiscuous Gα has yet been demonstrated to be truly universal with regard to its ability to couple to all known GPCR classes, the application of promiscuous G protein remains a valuable approach for receptor de-orphaning. In drug screening, promiscuous G proteins can also be used to couple well-characterized nonorphan receptors outside of the G q class to an easily detected signal output useful for high-throughput screening.
Even with the establishment of high-throughput screens, the identification of compounds that are both potent and selective remains a significant challenge in drug discovery. Standard screening campaigns assay a single target at a time. Although this can be a successful approach to identifying potent compounds, very little information about selectivity is generated. Multiplexed screens that examine the activity of compounds against multiple targets in parallel are necessary to efficiently address selectivity early in the drug discovery process. However, scaling assays to include multiple targets often requires changes in the assay platform as well as the generation of new reagents. Traditionally, much of the work involving GPCR de-orphaning and screening has relied on the timeconsuming generation of cell lines that have been stably transfected to express a receptor, often in conjunction with one or more promiscuous G proteins.
The recent development of reverse transfection technology provides a novel and efficient means of addressing some of the challenges pertinent to target screening in drug discovery. 11 The reverse transfection process as originally developed entails the robotic deposition of an array of discrete hydrogel-encapsulated plasmid DNA features onto a glass slide. Addition of cells and transfection reagent to these encapsulated DNA features results in the localized uptake of plasmid such that cells growing above a given feature will express the proteins encoded by the plasmid DNA contained within that feature.
In this report, we adapt reverse transfection technology to a 96well plate format and apply it to an analysis of the ligand-induced activation of GPCRs. Transient reverse transfection of GPCRs with promiscuous Gα subunits in combination with treatment with libraries of potential ligands or antagonists allows for the parallel analysis of combinations of GPCRs, G proteins, and small molecules. We demonstrate the utility of the reverse transfection technology to the process of GPCR de-orphaning and GPCR-targeted drug discovery, and we provide examples of ligand selectivity analysis against a panel of GPCRs as well as dose-dependent titrations of selected agonists and antagonists.
MATERIALS AND METHODS

Expression vectors
Mammalian expression-ready pcDNA3.1/GS constructs containing cDNAs of the human GPCRs adenosine A 2a receptor (ADORA2A), adenosine A 2b receptor (ADORA2B), β 2adrenergic receptor (ADRB2), chemokine (C-X-C motif) receptor 4 (CXCR4), chemokine (C-X-C motif) receptor 5 (CXCR5), complement component 5 receptor 1 (C5R1), chemokine-like receptor 1 (CMKLR1), endothelial differentiation sphingolipid GPCR 3 (EDG3), formyl peptide receptor 1 (FPR1), GPCR 39 (GPR39), and histamine receptor H 1 (HRH1) were purchased from Invitrogen (Carlsbad, CA). cDNAs encoding the human GPCRs α 1A -adrenergic receptor (ADRA1A), muscarinic M 1 receptor (CHRM1), muscarinic M 3 receptor (CHRM3), muscarinic M 4 receptor (CHRM4), angiotensin II receptor-like 1 (AGTRL1), bradykinin receptor B 1 (BDKRB1), chemokine (C-X-C motif) receptor 6 (CXCR6), chemokine (C-C motif) receptor 1 (CCR1), chemokine (C-C motif) receptor 5 (CCR5), dopamine receptor D 1 (DRD1), endothelial differentiation sphingolipid GPCR 5 (EDG5), putative purinergic receptor (FKSG79), GPCR 17 (GPR17), GPCR 19 (GPR19), GPCR 30 (GPR30), GPCR 35 (GPR35), GPCR 43 (GPR43), GPCR 45 (GPR45), GPCR 68 (GPR68), GPCR 75 (GPR75), melanocortin MC 1 receptor (MC1R), melanocortin MC 3 receptor (MC3R), purinergic receptor P2Y 1 (P2RY1), purinergic receptor P2Y 2 (P2RY2), and platelet-activating factor receptor (PTAFR) were PCR-amplified from human genomic DNA (BD Biosciences, San Jose, CA) using High Fidelity PCR Supermix (Invitrogen). In some cases, a 2-step PCR was employed to remove introns. The cDNA encoding Gα 16 , plus its native stop codon, was PCR-amplified from IMAGE clone 3878770 (Open Biosystems, Huntsville, AL). Amplified fragments were then cloned into the pDONR-201 entry vector and transferred into the mammalian expression vector pcDNA-DEST40 using the GATEWAY system (Invitrogen). All GPCR expression constructs encode a V5-epitope tag at their C-termini. The GFP expression construct pEGFP-N1 was purchased from BD Biosciences Clontech (Palo Alto, CA). DNA preparations for the printing of arrays were amplified in DH5α competent cells (Invitrogen), and DNA was purified using a Single Bridge Biomek FX96 robot (Beckman, Fullerton, CA) with Qiagen miniprep kits (Santa Clara, CA).
Cartesian Prosys 5210 DNA microarrayer (Genomic Solutions, Ann Arbor, MI) equipped with Telechem International SMP10B pins (Sunnyvale, CA) at a pitch of 550 µm. GPCR expression constructs were printed at a concentration of 60 ng/µl either with or without an expression construct encoding Gα 16 (also at 60 ng/µl). GFP features were printed at 10 ng/µl. All printing samples were normalized to a final concentration of 120 ng/µl with Bluescript II KS+ plasmid (Stratagene, Cedar Creek, TX). Printed arrays were stored at -20°C until reverse transfection.
Cell culture and transfection
HEK293T cells (provided by Dr. David Sabatini, Whitehead Institute, Cambridge, MA) were cultured in Dulbecco's modified eagle medium (D-MEM) with high glucose (Invitrogen, Carlsbad, CA) + 10% FBS (Omega Scientific, Tarzana, CA) + penicillinstreptomycin (Invitrogen). Immediately before transfection, cells were trypsinized with Trypsin-EDTA (Invitrogen) and resuspended in growth medium at a density of 4 × 10 5 cells/ml. Printed arrays were equilibrated for 15 min at room temperature before transfection. 60 µl of premixed Effectene transfection reagent cocktail (Qiagen, Santa Clara, CA) was added to each well and incubated for 30 min at room temperature. Wells were then washed with D-MEM and seeded with cells at a density of 4 × 10 4 cells/ well. Reverse-transfected cells were incubated for 48 h at 37°C in a 5% CO 2 -humidified environment.
Calcium flux assay
Forty-eight hours after reverse transfection, growth medium was removed and the cells were washed 3 times with 170 µl of room temperature Hank's balanced salt solution (HBSS) modified with 10 mM HEPES (Stemcell Technologies, Vancouver, Canada). 100 µl of 5 µM Fluo-4 calcium-binding dye (Molecular Probes, Eugene, OR) was then added to the cells of each well and incubated for 1 h at 25°C in a 5% CO 2 -humidified environment. The Fluo-4 solution was then removed, the cells were washed 3 times with 170 µl of room temperature HBSS modified with HEPES + 0.5% BSA, and the same buffer was added to a final volume of 125 µl per well. All manipulations were performed with a Single Bridge Biomek FX96 robot (Beckman, Fullerton, CA).
Agonist and antagonist solutions were prepared in HBSS modified with HEPES + 0.5% BSA. Agonist solutions were made up at 2× the final concentration, whereas antagonists were made as 10× concentrates. For agonist stimulation experiments, 125 µl of the 2× agonist solution was added to the appropriate wells. For antagonist inhibition experiments, 12.5 µl of 10× antagonist solution was added to the appropriate wells and incubated for 30 min at room temperature before the addition of 137.5 µl 2× agonist solution. Image acquisition was performed on an Axiovert 200M microscope (Zeiss, Thornwood, NY) using a 2.5× objective, a 470-Ex/ 525-Em filter set (Chroma, Brattleboro, VT), and an Axiocam MRm CCD camera. Image acquisition was driven by Axiovision v3.1 (Zeiss) with camera settings of bin 4, gain 3, and an exposure time of 100 ms. Images were captured at 3-second intervals over a period of 16 cycles. In all experiments, agonist was added after the completion of the 2nd imaging cycle (3 seconds into timelapse). Agonists and antagonists were purchased from R&D Systems (Flanders, NJ), Sigma-Aldrich (St. Louis, MO), Tocris Cookson (Ellisville, MO), and BioSource International (Camarillo, CA).
Immunofluorescence
Cells were fixed in 3.7% paraformaldehyde + 4% sucrose at room temperature for 20 min, washed with PBS, and then blocked and permeabilized with 0.1% TritonX-100 + 0.1% BSA at room temperature for 1 h. Cells were incubated overnight at 4°C with mouse anti-V5 (Invitrogen, Carlsbad, CA) and rabbit anti-Gα 16 (Torrey Pines Biolabs, Houston, TX). Cells were then washed in PBS, blocked, and incubated with anti-mouse Alexa 555 and antirabbit Alexa 488 secondary antibodies (Molecular Probes, Eugene, OR) at room temperature for 2 h. All manipulations were performed using a Single Bridge Biomek FX96 robot (Beckman, Fullerton, CA). Image acquisition was performed on a Axiovert 200M microscope (Zeiss, Thornwood, NY) using a 2.5× objective and 470-Ex/525-Em and 545-Ex/620-Em filter sets (Chroma, Brattleboro, VT).
Image extraction and analysis
Calcium flux and immunofluorescence images were extracted with ArrayVision v6.0 (Imaging Research Inc., St. Catherines, Canada) and analyzed in Excel (Microsoft, Redmond, WA). Fluorescent values of individual features were calculated by taking the average fluorescence of the cells in a feature and subtracting from it the median background fluorescence of neighboring nontransfected cells. Calcium flux curves were generated by subtracting the preagonist fluorescent value of a feature (t = 0 sec) from the postagonist fluorescent values. Dose-response curves were generated by plotting the peak stimulation values (t = 15 sec) from the calcium flux curves. EC 50 and IC 50 values were generated by nonlinear regression analysis in Prism v3.02 (GraphPad, San Diego, CA). P-values were generated in Excel using the Student's t-test (1-tailed distribution, 2-sample unequal variance). Immunofluorescence data were used to filter the data set by removing from the analysis selected features that displayed little to no protein expression.
RESULTS
Development of the reverse transfection cell microarray in a 96-well plate format
Reverse-transfected cell microarrays are generated by printing hydrogel-encapsulated DNA in discrete array patterns on a solid surface. Addition of cells and transfection reagents to these DNA arrays results in the creation of distinct cell clusters, each of which produces a protein encoded by the expression vector printed at a given feature. The reverse transfection technology was originally developed using a glass slide format 11 and has now been extended to a 96-well plate format ( Fig. 1 ). Hydrogel-encapsulated cDNA expression vectors are printed into the bottom of tissue culturetreated 96-well plates, and transiently transfected into HEK293T cells to create an array of transfected cell clusters, with each cluster comprising 100 to 200 transfected cells. In this format, each well contains a 6 × 6 array of 36 features, which allows for more than 3400 distinct features to be contained within a 96-well plate.
Reverse transfection in a 96-well plate format, like reverse transfection on glass slides, allows for substantial assay flexibility. The rapid generation of desired phenotypes through transient transfection and the capacity to transfect combinations of multiple plasmids at each feature creates an extremely versatile experimental platform. In addition, reverse transfection in a 96-well plate permits compound screening and titrations, allows standard laboratory automation equipment to be used for assay processing, and takes place in an environment that is better suited for cell growth and response than on glass slides.
Development of a multiplexed GPCR assay
A multiplexed GPCR calcium flux assay using reverse transfection technology in 96-well format is depicted in Figure 2 . We printed an array of cDNAs encoding GPCRs in selected wells of a 96-well plate and reverse transfected the arrays with HEK293T cells. After 48 h, the cells were loaded with the Fluo-4 calcium indicator dye, each well was treated with a single agonist at a given concentration, and the response was captured by timelapse photography over the course of 45 seconds using fluorescence microscopy (preagonist image Fig. 2A ; peak stimulation of postagonist image Fig. 2B ). We calculated the average change in fluorescent intensity over time for each receptor:agonist combination across multiple features to generate a plot depicting the calcium flux profile as a function of time ( Fig. 2C ). Dose-response curves were generated by plotting the peak stimulation values (t = 15 sec) from the calcium flux curves against the agonist concentration ( Fig. 2D ).
In this multiplexed GPCR assay, as many as 32 different GPCRs can be printed in a single well leaving 4 features to be used as GFP orientation markers. The quantitative analysis of numerous receptor:agonist combinations in this format demonstrate that fully stimulated, active receptors generally display feature-tofeature C.V.s of approximately 30% to 40%. As a result, we have typically measured each receptor:agonist combination in replicates of 3 to 6 features across multiple wells.
GPCR agonist selectivity screen
We evaluated the ability of the reverse transfection-based multiplexed GPCR calcium flux assay to serve as an agonist selectivity screening tool by creating an array of 36 different GPCRs in the absence and presence of a promiscuous Gα 16 . The cells were loaded with Fluo-4 calcium indicator dye and measured for calcium flux response to 25 different agonists. A single concentration was used for each agonist: 0.8 µM for chemokines and 10 µM for all others. In the absence of Gα 16 , 5 of the 36 GPCRs demonstrated a calcium flux response to at least 1 of the 25 agonists ( Fig. 3 , left panel). These 5 receptors (adrenergic α 1A , muscarinic M 1 and M 3 , histamine H 1 , and PAF) are all known to signal through a G q pathway, 12 and thus likely signaled through the endogenous Gq found in HEK293T cells. In the presence of cotransfected Gα 16 , an additional 6 receptors responded to at least 1 agonist ( Fig. 3 , right panel). These 6 GPCRs include G i (muscarinic M 4 , fMLP, and chemokine CXCR4 and CXCR6) and G s (adrenergic β 2 and dopamine D 1 ) pathway receptors, which do not generally signal through a calcium flux pathway. [12] [13] [14] Table 1 summarizes the data obtained from all 36 receptor:25 agonist combinations (900 total combinations) in the presence of cotransfected Gα 16 . Positive responses (which are highlighted) are defined by having a minimum signal of 9 fluorescent units and a Pvalue ≤ 0.05. Eleven of the 36 receptors and 10 of the 25 agonists participated in the generation of a calcium flux response, yielding a total of 15 positive responses out of a possible 900. Of these 15 positive combinations, 14 reflect well-characterized receptor:agonist pair interactions. 12, 13, 15, 16 Although not a well-characterized interaction, consistent and reproducible stimulation of histamine H 1 receptor by salbutamol was observed. Salbutamol, normally considered a β 2 adrenergic agonist, has been shown to inhibit stimulation by histamine if used as a pretreatment. 17 This is consistent with salbutamol stimulation of histamine H 1 receptor followed by desensitization, which makes it subsequently unresponsive to histamine. Although 9 well-characterized receptor:agonist pairs, including melanocortin MC 1 :NDP-MSH, melanocortin MC 3 :NDP-MSH, APJ:apelin-13, bradykinin B 1 :des-arg 10 -kallidin, CCR1: RANTES, CCR5:RANTES, CXCR5:BCA-1, GPR43:propionate, and GPR68:SPC, did not elicit a calcium flux response, we did not observe any false positives. Ten of the 36 receptors that we tested were orphan receptors with no known ligands, and although none of these orphans were stimulated by any of the 25 agonists, the assay clearly provides a useful platform for the multiplexed analysis of GPCR de-orphaning. For an ideal de-orphaning screen, we would employ a broad panel of naturally occurring molecules and extracts from tissues, biological fluids, and cell supernatants.
Dose-dependent agonist stimulation
We chose 4 agonist:receptor pairs from the agonist selectivity screen for more detailed examination. HEK293T cells were reverse transfected with arrayed cDNAs encoding muscarinic M 3 , adrenergic α 1A and β 2 , and dopamine D 1 receptors in the absence and presence of a cDNA encoding Gα 16 , loaded with Fluo-4 calcium indicator dye, and measured for calcium flux response to increasing concentrations of agonist. The resultant data were then utilized to generate dose-response curves and EC 50 values. M 3 and α 1A were examined for their response to carbachol, mcn-A-343, and A61603 in the absence of Gα 16 (Fig. 4A ). M 3 responded to carbachol and mcn-A-343 with EC 50 values of 240 nM and 2.1 µM, respectively, whereas α 1A responded to A61603 with an EC 50 value of 2.8 nM. M 3 and α 1A are G q class receptors that are able to utilize endogenous G q and therefore did not require the presence of Gα 16 in this assay. In contrast, the G s -class β 2 , and D 1 receptors did require the presence of Gα 16 to produce a calcium flux signal (Fig.  4B ). Salbutamol stimulated β 2 with an EC 50 value of 710 nM, whereas fenoldopam stimulated D 1 with an EC 50 value of 190 nM.
Features transfected with cDNAs encoding β 2 , D 1 , or Gα 16 alone did not respond to agonist. The observed agonist EC 50 values for all of the receptors are consistent with published results [18] [19] [20] [21] [22] [23] and demonstrate the utility of GPCR cell microarrays in simultaneously determining agonist potency and selectivity.
Dose-dependent antagonist inhibition
We also evaluated the ability of GPCR cell microarrays to measure antagonist activity. cDNAs encoding M 3 and D 1 receptors in conjunction with a cDNA encoding Gα 16 were reverse transfected into HEK293T cells, which were then loaded with Fluo-4 calcium indicator dye and exposed to increasing concentrations of antagonist. After cells were incubated with antagonist for 30 min, agonist was added, the calcium flux response was measured, and doseresponse curves were generated. Pirenzepine and 4-DAMP inhib- Fig. 5, left panel) . Antagonist-mediated receptor desensitization prior to the addition of agonist was not observed, as none of the 4 antagonists investigated displayed any agonist activity toward their respective receptors (data not shown). The observed antagonist IC 50 values are consistent with published results 16, 24, 25 and demonstrate the utility of GPCR cell microarrays in determining antagonist potency. Furthermore, these results demonstrate that the multiplexed GPCR calcium flux assay can be used as a primary selectivity screen for antagonists directed against a family of receptors that share a common agonist.
Multiplex GPCR Assay
DISCUSSION
To address the challenges associated with developing liganded and orphan GPCRs as drug targets, we have created a multiplexed transient transfection assay that enables receptor de-orphaning and simultaneous potency and selectivity screening for agonists and antagonists. This assay combines reverse transfection in a 96well plate format with a calcium flux readout and is capable of measuring greater than 3000 receptor:ligand interactions in a sin-gle plate. We have determined agonist EC 50 and antagonist IC 50 values for a number of well-documented ligand:GPCR pairs and have found our values to be consistent with previously published results, demonstrating the utility of applying this approach to GPCR-based drug discovery.
Identifying a compound with the desired selectivity and potency greatly improves the chances of generating a drug with the desired efficacy. Many drugs, including those targeting GPCRs, have undesirable side effects that result from off-target interactions. [26] [27] [28] For GPCRs, these off-target interactions can include drug action upon receptors in either different subtype classifications (eg, dopamine, histamine, serotonin, etc) or within the same subtype. The lack of high-throughput multiplexed GPCR screening assays has often made it difficult to determine potency and selectivity early in the drug development process. However, the multiplexed GPCR assay we have developed provides a platform for the direct comparison of potency and selectivity within a single experiment. We screened a panel of 36 GPCRs for their response to 25 agonists and identified 15 functional GPCR:agonist interactions out of a set of 900 possible combinations, demonstrating the applicability of the assay to selectivity screening. Because each well of a 96-well plate can contain up to 32 unique GPCRs, an entire subfamily could be printed within a single well, or all nonchemosensory receptors could be printed within a single plate row. Hence, the application of reverse transfection technology enables the efficient screening of thousands of compounds against entire classes of receptors. Although 9 well-characterized receptor:agonist pairs did not elicit a calcium flux response, we did not observe any false positives. The inability of some receptors in the panel to respond to their associated agonists may result from the functional inactivation of the receptor by the presence of the V5-epitope tag or low ligand potency, or may simply reflect the inability of the receptor to couple to Gα 16 and signal through the G q pathway to produce a calcium flux. The ability of the calcium flux readout to serve as a universal assay for all GPCRs is dependent upon the presence of the appropriate G protein. Ligand-induced calcium release is a hallmark of the activation of the G q family of receptors, whereas G i -and G s -coupled receptors require a promiscuous G protein to efficiently link them to the calcium mobilization pathway. Cotransfection of promiscuous Gα 16 has been used to expand the range of receptors that can be used in this assay, and additional promiscuous G proteins could be used to further broaden the functional scope of the assay. [5] [6] [7] [8] Use of cotransfected Gα 16 has also been shown to permit dosedependent measurement of antagonist activity. Because there is as of yet no truly universal G protein, it is often necessary to test multiple variants of promiscuous G proteins to identify one that is able to efficiently interact with a given receptor. This is particularly true when dealing with orphan GPCRs, which lack known ligands and characterized signaling pathways. Transient cotransfection of cDNAs encoding G proteins and receptors in the reverse transfection format permits efficient coupling of non-G q receptors to a calcium release readout.
The ability to rapidly create cells with the desired phenotype through transient transfection coupled with the multiplexed 96well plate format makes reverse transfection ideally suited for de-veloping screens for target validation and de-orphaning. Investigators have traditionally used stably transfected cell lines for GPCR screening assays. Such stably transfected cells offer the advantage of creating a uniform population of cells that all respond to agonist, but generating stable cell lines is a time-consuming and laborious process. In addition, the generation of stable cell lines for GPCR:G protein combinations is not practical and thus requires a transient transfection system. Performing complex pairwise cotransfections with a set of GPCRs and a panel of G proteins is made both routine and accessible by reverse transfection cell arrays: deorphaning using reverse transfected cell microarrays would require 5 wells to print all 143 orphan receptors, 15 wells to combine 143 receptors with 3 different promiscuous G proteins, and 90 wells to screen all combinations against a single compound in replicates of 6 features. Therefore, it would require 100 plates to screen 100 compounds against 143 orphan receptors in combination with 3 promiscuous G proteins. For comparison, 750 384-well plates would be required to generate a similar data set using a standard whole-well FLIPR assay.
The 96-well reverse transfection format is a viable platform not only for testing combinations of GPCRs and G proteins but also for testing the combinatorial expression of different GPCRs. Oligomerization of receptors is a well-established facet of GPCR biology. 29 Receptors can form homo-oligomeric and heterooligomeric complexes, and these heteromeric complexes often display functional properties that are different from those of their constituent receptors alone. This presents both a great challenge for understanding GPCR biology and a significant opportunity for GPCR drug discovery. Most GPCR drug discovery efforts are aimed at discovering ligands against monomeric or homooligomeric forms of receptors. However, some orphan receptors may function only as heteromeric complexes, and some liganded receptors may have novel properties in their physiological environment when complexed with other receptors. Hetero-oligomeric receptors, therefore, can be considered as novel targets for drug discovery. The multiplexed GPCR assay we have developed is well suited to a combinatorial approach to de-orphaning and heteromeric receptor screening, since 32 experimental features per well in a 96-well plate format would permit more than 3000 combinations per plate to be examined.
Multiplex GPCR Assay
The transient nature, scalability, and ease of implementation of the reverse transfection-based GPCR screening assay make it both tractable and appealing as a drug discovery platform. However, there are some challenges associated with use of transient transfections and large clone sets. Feature-to-feature variation in the cell microarray format is typically greater than the well-to-well variation observed in standard cell-based assays, and not all clones will express active protein. We have been able to compensate for increased variation by screening replicate features, and preliminary data suggest that normalization of signal to protein expression may also reduce variation. Lack of clone expression or activity can be partially controlled for by the use of V5 tagged and nontagged clone collections. Although not all aspects of the reverse transfection GPCR screening assay are currently automated, the entire process can be automated. In these experiments, agonist stimulation was performed by addition of compound to individual wells using hand pipetting, and timelapse photography of individual wells was manually initiated immediately prior to compound addition. Significant scaling of this assay would require the automation of compound addition and of image capture capacities that have already been established and are commercially available. An alternative approach would be to reconfigure the assay into an endpoint readout using a reporter assay, such as beta-lactamase, 30, 31 in order to permit uncoupling of the compound addition and image capture steps and to allow simultaneous compound addition to entire plates using a 96-head multichannel pipetting robot.
CONCLUSIONS
We have developed a multiplexed whole-cell assay for potency and selectivity testing of GPCR agonists and antagonists. This assay uses reverse transfection technology in a 96-well plate format to create arrays of distinct cell clusters, each expressing a different GPCR or GPCR:G protein combination. The reverse transfection cell microarray platform has a number of attractive features, including 1) rapid generation of a desired phenotype through transfection, 2) the ability to combine multiple plasmids at each feature, 3) a consistent environment across multiple data points within each well, and 4) compatibility with standard microplates and with a variety of semiautomated or automated systems. This assay system can be used to identify ligands for orphan receptors, to rapidly develop screening assays for validated targets, and to identify agonists or antagonists with a desired selectivity profile. We anticipate that reverse transfection cell microarrays will provide a valuable new drug discovery platform not only for GPCRs but also for other gene families, such as ion channels, in which combinatorial expression of target proteins and accessory factors may be beneficial.
